Melinta Therapeutics Announces Appointment of Jisoo Park as Head of Business Development, M&A and Strategy

By: Melinta Therapeutics, LLC via Business Wire

July 06, 2021 at 08:00 AM EDT

Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announces the appointment of Jisoo Park as Head of Business Development, M&A and Strategy, effective today.

Jisoo Park, a leader in global pharmaceutical business development, joins Melinta under the leadership of President and Chief Executive Officer Christine Ann Miller. With the addition of Mr. Park, Melinta expects to expand its world-class portfolio with additional products that address therapeutic areas of critical need.

“At Melinta, we’re committed to expanding our portfolio to continue to serve patients with unmet needs. I’m excited to have Jisoo in this role as someone who shares our passion and purpose,” Ms. Miller said. “He has a proven track record in global pharmaceutical business development and I know he’ll be an incredible partner in helping us achieve our vision.”

Said Mr. Park, “Melinta is on a mission to make the most meaningful impact for patients with life-threatening illnesses and I’m excited to join the team in the middle of such great momentum. I look forward to working with this truly committed team toward continued growth and expansion to serve patients in need in the U.S. and beyond.”

Mr. Park joins Melinta from Covis Pharma where he served as Vice President of Business Development and M&A. At Covis, he led global business development and M&A, including transformational buy-side and sell-side M&A, licensing and financings. In less than five years, Jisoo led seven deals worth roughly $2 billion in transaction value, helping to expand the organization beyond the U.S. and into more than 50 markets.

Prior to Covis, he was an investment banker in J.P. Morgan’s Global Healthcare team in New York and San Francisco, where he advised companies in the pharmaceuticals, biotech and life sciences industries on M&A, equity and debt financings.

About Melinta Therapeutics

Melinta Therapeutics, LLC provides innovative therapies to people impacted by acute and life-threatening illnesses. Our portfolio currently includes five commercial-stage antibiotics: Baxdela® (delafloxacin), Kimyrsa™ (oritavancin), Minocin® (minocycline) for Injection, Orbactiv® (oritavancin), and Vabomere® (meropenem and vaborbactam). With an unsurpassed commitment to providers and the patients they serve, we work to ensure that all people who need our therapies can receive them. We focus our expanding portfolio on serving patients with an unmet need because that’s how we make the most meaningful impact. At Melinta, we’re visionaries dedicated to innovation while staying grounded in what matters most: patients. Visit www.melinta.com for more information.